36results about How to "Reduce wet weight" patented technology

The invention relates to a pharmaceutical compound and a preparation method and a preparation thereof, in particular to a pharmaceutical compound for curing prostatitis and prostate hyperplasia and a preparation method and a preparation thereof. The pharmaceutical compound is prepared by the following traditional Chinese medicine raw materials according to the parts by weight: 60-100 parts of wuling powder, 20-80 parts of zedoary, 20-80 parts of fritillaria thunbergii and 20-40 parts of alisma orientale. The invention also discloses the preparation method and the preparation of the pharmaceutical compound. The pharmaceutical compound and the preparation thereof have good curative effects to prostatitis and prostate hyperplasia without side effects.

The invention relates to a disease preventing and curing medicinal mouth-muffle and a medicinal composite. The disease preventing and curing medicinal mouth-muffle (1) comprises a mouth-muffle body (2), one surface of the mouth-muffle body (2) is provided with an insert pocket (3), and a powder bag (4) which packages the medicinal composite is placed in the insert pocket (3). The medicinal composite comprises the following Chinese herbs by weight: 2.2 percent of chrysanthemum and muskiness, 4.2 percent of cinnamon, good ginger, long pepper, radix aconite, frankincense, myrrh and clove, 5.0 percent of vermilion, 6.4 percent of asarum, eaglewood, croton, resina draconis, early plum flowers and rhizoma ligustici wallichii and 7.6 percent of tooth soap, arsenic sulphide and brain sand. The disease preventing and curing medicinal mouth-muffle internally carries the medicinal composite which plays a role during the mouth-muffle wearing process, thereby having disease prevention and cure and being simple and direct and also effective in treatment.

The invention relates to a medicinal preparation for treating benign prostate hyperplasia and process for its preparation, wherein the medicament is prepared from astragalus root, peach kernels, zedoary, rhubarb horsetails, poria cocos, coix seed, motherwort, selfheal, Cinnamomum cassia, root of ballon flower, subprostrate sophora root, achyranthes and cyathula root, and medicinal auxiliary materials.

GLP-2 analogs, such as teduglutide, and fusion proteins of GLP-2 with immunoglobulin are administered before, during or after surgery, particularly resection of the small intestine. When short bowel syndrome develops after surgical resection of the small intestine, parenteral nutrition is usually necessary to compensate for reduced absorption of water and nutrients across the small intestine. GLP-2 analogs and GLP-2 fusion proteins promote growth of small intestine, improve nutrient absorption and can reduce the need for parenteral nutrition after surgery.

The invention relates to a solar cell with three gate electrode structures. A front face gate line structure comprises three symmetrical primary gate lines and a plurality of evenly distributed secondary gate lines perpendicular to the primary gate lines, one primary gate line is located on the center line of a silicon wafer, and the two ends of each primary gate line and the part, connected with the corresponding primary gate line, of each secondary gate line are respectively of a gradual change type structure. A back face structure comprises three primary gate lines corresponding to the front face gate lines, and asymmetric direction signs smaller than the width of the gate lines exist in the grate line direction. According to the gradual change type structures of the two ends of the primary gate lines, the two ends of each primary gate line gradually narrow down and are of a trapezoid gradual change stricture. According to the gradual change stricture of each secondary gate line, in the junction of the secondary gate line and the corresponding primary gate line, the width of the position, close to the corresponding primary gate line, of the secondary gate line is large, the secondary gate line gradually narrows down when far away from the corresponding primary gate line, and when the secondary gate line reaches a certain length, the width of the secondary gate line is the smallest and will no longer change. The solar cell with the three gate electrode structures can lower cell cost, improve the efficiency of solving problems, and improve the efficiency of a battery piece to a certain extent.

The invention relates to a medicine for treating benign prostatic hyperplasia and a preparation method thereof. Composed of pharmaceutical excipients. The preparation method is to crush cinnamon, rhubarb, coix seed, and peach kernel into fine powder; extract volatile oil from curcuma decoction pieces; Decoction pieces, zedoary dregs, water-extracted filtrate and astragalus ethanol liquid are combined and concentrated to make a dry paste, crushed, sieved, added zedoary volatile oil and fine powder of cinnamon and other drugs, and made into various preparations with medicinal excipients. The preparation can obviously inhibit the hyperplasia of prostate tissue induced by testosterone, significantly reduce the wet weight and dry weight of each leaf of the prostate, has no obvious toxic effect, and is safe and reliable; the preparation method has high bioavailability, good drug effect, stable quality and easy control.

The invention discloses a chrysanthemum total flavone granule, which is made of the following raw materials in the weight ratio: sucrose powder: dextrin: dry extract powder of the total flavonoids of chrysanthemum = 0.5-1.5: 1.5-2.5: 0.5-1.5 . The present invention prepares chrysanthemum total flavonoids into granules. The granules have good formability, properties, particle size, water content, solubility, etc. all meet the requirements, and the quality is controllable and the stability is good. The color changes, the smell is lost, the content of active ingredients decreases, and the color of the item in the soaking process does not turn green. Chuju total flavonoids granules can significantly prolong the coagulation time of rats with cold coagulation and blood stasis syndrome, reduce the length of thrombus in vitro and dry and wet weight, reduce hematocrit, slow down erythrocyte sedimentation rate, and increase serum NO content. The product is easy to drink and carry, easy to store, has no toxic and side effects, and has the characteristics of preventing, treating and improving abnormal blood rheology in rats with blood stasis.

Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.

The invention relates to the technical field of medicine research and development, in particular to application of a flavone C-glycoside compound in preparation of medicine for preventing or treating acute lung injury and / or acute respiratory distress syndrome, the flavone C-glycoside compound has a structure shown in the following formula, R1-R8 are defined in the specification, and the flavone C-glycoside compound has a structure shown in the specification. The flavone C-glycoside compound provided by the invention can obviously inhibit inflammatory response, inhibit release of inflammatory factors and reduce the content of inflammatory factors in alveolar lavage fluid and serum, and also can obviously inhibit pulmonary edema, reduce generation of pulmonary effusion and reduce wet weight of lungs; the increasing degree of the ratio of wet weight to dry weight of lung caused by acute lung injury is inhibited, so that the effects of resisting inflammation and inhibiting lung edema are achieved.

The invention discloses a novel ferulic acid derivative, its application and a synthetic method thereof. The novel ferulic acid derivative is a compound as shown in the formula (I), wherein R1 and R2 are respectively C1-10 alkyl. According to the compound as shown in the formula (I), ferulic acid molecule is used as the base. By modification or reconstruction of the side-chain structure of the ferulic acid molecule, stability of ferulic acid is raised, and its pharmacological effects are substantially enhanced.

The invention provides a medicinal liquor for alleviating clinical symptoms of reddening and swelling and heat pain. The medicinal liquor has a formula containing 400-600 parts by weight of alcohol and the following medicinal materials immersed in the alcohol in parts by weight: 2-4 parts of rheum officinale, 2-4 parts of scutellaria baicalensis, 2-4 parts of phellodendron, 2-4 parts of coptis, 2-4 parts of garden burnet, 2-4 parts of white peony root, 4-6 parts of salvia miltiorrhiza and 4-6 parts of safflower. The medicinal liquor for alleviating the clinical symptoms of reddening and swelling and heat pain has substantial treatment effect, simple material selection and no toxic and side effects during clinical use.

The invention discloses an application of arctiin in preparation of a medicine for treating prostatic hyperplasia. Arctiin is a main active substance in fructus arctii, and it is found that arctiin can significantly reduce the wet weight and prostate index of prostate of a model animal and can be applied to treatment of prostatic hyperplasia. The arctiin is definite in curative effect and small in toxic and side effects, is expected to be developed into the prostatic hyperplasia medicine, and has a wide medical application prospect.

The invention relates to a disease preventing and curing medicinal mouth-muffle and a medicinal composite. The disease preventing and curing medicinal mouth-muffle (1) comprises a mouth-muffle body (2), one surface of the mouth-muffle body (2) is provided with an insert pocket (3), and a powder bag (4) which packages the medicinal composite is placed in the insert pocket (3). The medicinal composite comprises the following Chinese herbs by weight: 2.2 percent of chrysanthemum and muskiness, 4.2 percent of cinnamon, good ginger, long pepper, radix aconite, frankincense, myrrh and clove, 5.0 percent of vermilion, 6.4 percent of asarum, eaglewood, croton, resina draconis, early plum flowers and rhizoma ligustici wallichii and 7.6 percent of tooth soap, arsenic sulphide and brain sand. The disease preventing and curing medicinal mouth-muffle internally carries the medicinal composite which plays a role during the mouth-muffle wearing process, thereby having disease prevention and cure andbeing simple and direct and also effective in treatment.

A freeze-dried powder injection ''Tongmai'' for treating coronary heart disease, angina pectoris and cerebral infarction is prepared proportionally from red sage root, Chuan-xiong rhizome and pueraria root through respectively decocting, vacuum concentrating and depositing in alcohol to obtain their extracts, mixing, adding sodium hydrogen sulfite and manna and conventionally preparing injection.

The invention belongs to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicinal composition as well as a preparation method and an application thereof. The traditional Chinese medicinal composition is prepared from pseudo-ginseng, radix puerariae, radix paeoniae rubra, safflower carthamus, peach kernels, herba siegesbeckiae, dragon's blood, hematoxylon, rhizoma chuanxiong, earthworm, leech and radix achyranthis bidentatae. The preliminary pharmacodynamics study proves that the traditional Chinese medicinal composition and a medicine provided by the invention have obvious antithrombus effects (P is smaller than 0.05) in the aspects of prolonging the in-vivo thrombogenesis time, reducing the in-vitro thrombus wet weight and dry weight, and inhibiting the platelet aggregation effect, and therefore, the traditional Chinese medicinal composition has an obvious antithrombus curative effect (P is smaller than 0.05).

The invention relates to the technical field of medicine research and development, in particular to application of an isopentenyl flavonoid compound in preparation of a medicine, the medicine can be used for preventing or treating acute lung injury and / or acute respiratory distress syndrome, the isopentenyl flavonoid compound has a structure as shown in a formula 1, and definitions of R1-R10, M, X and k are recorded in the specification. The isopentenyl flavonoid compound provided by the invention can obviously inhibit inflammatory response, inhibit release of inflammatory factors, reduce the content of inflammatory factors in alveolar lavage fluid and serum, and also can obviously inhibit pulmonary edema, reduce generation of pulmonary effusion and reduce wet weight of lungs, so that the lung quality is improved. The increasing degree of the ratio of wet weight to dry weight of lung caused by acute lung injury is inhibited, so that the effects of resisting inflammation and inhibiting lung edema are achieved.